**Table S1. Baseline characteristics, laboratory findings and outcomes before and after propensity score matching between two groups**.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Before propensity score matching | | | After propensity score matching | | |
| Characteristics | Younger group  (n = 159) | Elderly group  (n = 98) | *p* value | Younger group  (n = 44) | Elderly group  (n = 44) | *p* value |
| Age, years | 55.0 (46.0-60.0) | 72.5 (69.0-78.0) | < 0.0001 | 58.0 (53.5-60.0) | 71.0 (68.0-76.5) | < 0.0001 |
| Gender |  |  | 0.7507 |  |  | >0.9999 |
| Male | 86 (54.1%) | 55 (56.1%) |  | 26 (59.1%) | 26 (59.1%) |  |
| Female | 73 (45.9%) | 43 (43.9%) |  | 18 (40.9%) | 18 (40.9%) |  |
| Charlson comorbidity index | 1.0 (1.0-2.0) | 4.0 (3.0-5.0) | < 0.0001 | 2.0 (1.0-3.0) | 3.0 (2.5-4.0) | < 0.0001 |
| **Comorbidities** |  |  |  |  |  |  |
| Any of following | 72 (45.3%) | 68 (69.4%) | 0.0002 | 32 (72.7%) | 27 (61.4%) | 0.2595 |
| Hypertension | 38 (23.9%) | 59 (60.2%) | < 0.0001 | 21 (47.7%) | 22 (50.0%) | 0.8321 |
| Diabetes | 41 (25.8%) | 31 (31.6%) | 0.3117 | 18 (40.9%) | 14 (31.8%) | 0.3781 |
| Chronic kidney disease | 3 (1.9%) | 9 (9.2%) | 0.0118 | 2 (4.5%) | 1 (2.3%) | >0.9999 |
| Chronic obstructive pulmonary disease | 3 (1.9%) | 7 (7.1%) | 0.0464 | 1 (2.3%) | 1 (2.3%) | >0.9999 |
| Cardiovascular disease | 6 (3.8%) | 10 (10.2%) | 0.0386 | 4 (9.1%) | 4 (9.1%) | >0.9999 |
| Cancer | 4 (2.5%) | 10 (10.2%) | 0.0110 | 2 (4.5%) | 1 (2.3%) | >0.9999 |
| Body mass index, kg/m2 | 26.0 (23.4-28.5) | 24.8 (22.7-26.7) | 0.0198 | 26.1 (23.5-28.2) | 25.5 (23.3-28.8) | 0.6643 |
| **Laboratory results** |  |  |  |  |  |  |
| White blood cell count, ×109 /L | 6.0 (4.3-7.7) | 6.25 (4.7-8.5) | 0.3146 | 6.2 (4.9-7.5) | 6.9 (4.9-9.7) | 0.2121 |
| Absolute lymphocyte count, ×109 /L | 0.98 (0.67-0.28) | 0.89 (0.5-0.23) | 0.0951 | 0.89 (0.58-1.11) | 0.78 (0.48-1.20) | 0.7354 |
| D-dimer, ng/mL | 598.5 (363.5-1046.0) | 1070 (646.3-1872.0) | < 0.0001 | 939.5 (504.0-1272.5) | 975.0 (643.0-1483.5) | 0.2688 |
| Procalcitonin, ng/mL | 0.05 (0.05-0.11) | 0.05 (0.05-0.18) | 0.0095 | 0.06 (0.05-0.14) | 0.06 (0.05-0.22) | 0.7786 |
| C-reactive protein, mg/dL | 4.07 (1.22-9.89) | 5.36 (2.12-12.04) | 0.0513 | 7.33 (3.38-13.67) | 4.62 (2.37-14.19) | 0.6105 |
| Albumin, g/dL | 4.10 (3.70-4.30) | 3.70 (3.40-4.03) | < 0.0001 | 3.85 (3.60-4.20) | 3.70 (3.50-4.10) | 0.2110 |
| Ferritin, ng/mL | 379.5 (165.1-865.2) | 540.1 (336.9-1011.7) | 0.0005 | 550.0 (213.1-1087.4) | 703.2 (420.7-1186.0) | 0.3289 |
| Lactic dehydrogenase, U/L | 254.5 (175.5-373.5) | 255.0 (199.0-359.3) | 0.5433 | 336.0 (245.8-438.5) | 262.0 (189.5-354.5) | 0.0572 |
| Creatinine, mg/dl | 0.80 (0.70-1.00) | 1.00 (0.80-1.40) | 0.0001 | 1.00 (0.70-1.25) | 1.00 (0.80-1.50) | 0.6632 |
| **Treatment** |  |  |  |  |  |  |
| Systemic corticosteroid | 120 (75.5%) | 84 (85.7%) | 0.0491 | 41 (93.2%) | 41 (93.2%) | >0.9999 |
| Remdesivir | 47 (29.6%) | 48 (49.0%) | 0.0018 | 19 (43.2%) | 23 (52.3%) | 0.3960 |
| Tocilizumab | 42 (26.4%) | 32 (32.7%) | 0.2843 | 26 (59.1%) | 21 (47.7%) | 0.2881 |
| **Outcome** |  |  |  |  |  |  |
| Use of oxygen supplement | 109 (68.6%) | 81 (82.7%) | 0.0126 | 39 (88.6%) | 37 (84.1%) | 0.5368 |
| High-flow nasal cannula | 24 (15.1%) | 17 (17.3%) | 0.6326 | 18 (40.9%) | 12 (27.3%) | 0.1797 |
| Mechanical ventilation | 27 (17.0%) | 23 (23.5%) | 0.2027 | 19 (43.2%) | 15 (34.1%) | 0.3839 |
| Hospital duration of the survivors, days | 12.0 (9.0-16.5) | 15.0 (11.0-23.0) | 0.0006 | 14.5 (11.0-29.0) | 15.0 (11.0-22.0) | 0.8599 |
| In-hospital mortality | 3 (1.9%) | 7 (7.1%) | 0.0347 | 2 (4.5%) | 4 (9.1%) | 0.6763 |
| Discharged alive | 156 (98.1%) | 91 (92.9%) |  | 42 (95.5%) | 40 (90.9%) |  |